Capadenoson in Angina Pectoris
WithdrawnPhase 2NCT00518921
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This is a multi-center and multi-national,randomized, double blind, placebo-controlled, 28-day treatment study with BAY 68-4986 taken orally or a matching placebo.
Study details
- Official title
- Phase IIa Efficacy and Safety Trial of Capadenoson in Patients With Chronic Stable Angina
- Conditions
- Interventions
- Sponsor
- Bayer
- Start date
- 2008-03
- Sex
- All
- Age range
- from 35 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- Czechia, Hungary, Israel, Italy, Poland, Slovakia
- Total sites listed
- 36
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * The primary diagnosis is chronic stable angina of mild-moderate intensity as defined by the Canadian Cardiovascular Society Functional Class II-III, in the presence of definitive coronary artery disease. * Male or female subjects aged 35 to 75 years (if female, only if postmenopausal or permanently sterilized) * Stable angina of mild-moderate intensity (Canadian class II-III) with anti-anginal medication not changed for the last 5 weeks Exclusion Criteria: * Inability to withdraw current anti-anginal therapy * Inability to withdraw any concomitant therapy that would interfere with interpretation of study results
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00518921